Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current earnings are A$41.89 Billion. , an increase over its 2023 earnings that were of A$24.32 Billion. The earnings displayed on this page is the company's Pretax Income.